###begin article-title 0
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
Variation in GYS1 Interacts with Exercise and Gender to Predict Cardiovascular Mortality
###end article-title 0
###begin p 1
Conceived and designed the experiments: LG MO JC BI. Performed the experiments: MS JF. Analyzed the data: PA DA MO JF. Contributed reagents/materials/analysis tools: LG VL MT MO MS JC BI. Wrote the paper: LG VL PA DA MT MO MS JF JC BI.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
The muscle glycogen synthase gene (GYS1) has been associated with type 2 diabetes (T2D), the metabolic syndrome (MetS), male myocardial infarction and a defective increase in muscle glycogen synthase protein in response to exercise. We addressed the questions whether polymorphism in GYS1 can predict cardiovascular (CV) mortality in a high-risk population, if this risk is influenced by gender or physical activity, and if the association is independent of genetic variation in nearby apolipoprotein E gene (APOE).
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 362 366 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 564 568 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 681 685 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 723 727 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Polymorphisms in GYS1 (XbaIC>T) and APOE (-219G>T, epsilon2/epsilon3/epsilon4) were genotyped in 4,654 subjects participating in the Botnia T2D-family study and followed for a median of eight years. Mortality analyses were performed using Cox proportional-hazards regression. During the follow-up period, 749 individuals died, 409 due to CV causes. In males the GYS1 XbaI T-allele (hazard ratio (HR) 1.9 [1.2-2.9]), T2D (2.5 [1.7-3.8]), earlier CV events (1.7 [1.2-2.5]), physical inactivity (1.9 [1.2-2.9]) and smoking (1.5 [1.0-2.3]) predicted CV mortality. The GYS1 XbaI T-allele predicted CV mortality particularly in physically active males (HR 1.7 [1.3-2.0]). Association of GYS1 with CV mortality was independent of APOE (219TT/epsilon4), which by its own exerted an effect on CV mortality risk in females (2.9 [1.9-4.4]). Other independent predictors of CV mortality in females were fasting plasma glucose (1.2 [1.1-1.2]), high body mass index (BMI) (1.0 [1.0-1.1]), hypertension (1.9 [1.2-3.1]), earlier CV events (1.9 [1.3-2.8]) and physical inactivity (1.9 [1.2-2.8]).
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
Polymorphisms in GYS1 and APOE predict CV mortality in T2D families in a gender-specific fashion and independently of each other. Physical exercise seems to unmask the effect associated with the GYS1 polymorphism, rendering carriers of the variant allele less susceptible to the protective effect of exercise on the risk of CV death, which finding could be compatible with a previous demonstration of defective increase in the glycogen synthase protein in carriers of this polymorphism.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 152 155 152 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Bethesda1">[1]</xref>
###xml 337 340 337 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-1">[2]</xref>
###xml 803 806 803 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Rinn1">[3]</xref>
###xml 704 707 <span type="species:ncbi:9606">men</span>
###xml 712 717 <span type="species:ncbi:9606">woman</span>
Cardiovascular (CV) disease (CVD), including coronary heart disease (CHD) and stroke, is the leading cause of death and disability in the Western world [1] and is thought to result from a complex interaction between genetic and environmental factors. Such risk factors are age, male gender, smoking, hypertension, diabetes, dyslipidemia [2] and physical inactivity. The genetic constitution of an individual usually determines how the individual responds to these risk factors. Therefore, it is necessary not only to identify which genetic variants increase susceptibility to the disease but also which environmental risk factors act in concert with these genes. In addition, the cellular environment in men and woman can be very different given known differences in hormonal milieu and gene expression [3]. Therefore, it is reasonable to consider the possibility that gender specific gene-environment interactions could modify the penetrance and expression of the trait.
###end p 9
###begin p 10
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 310 313 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Groop1">[4]</xref>
###xml 314 317 314 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Fenger1">[8]</xref>
###xml 393 396 393 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Kadowaki1">[9]</xref>
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Rissanen1">[10]</xref>
###xml 719 723 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-StOnge1">[11]</xref>
###xml 725 729 725 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Pratley1">[12]</xref>
###xml 864 868 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-An1">[17]</xref>
###xml 883 887 883 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 993 997 993 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-An2">[18]</xref>
Muscle glycogen synthase is the key enzyme in the synthesis of glycogen in skeletal muscle. A polymorphism (XbaI) in intron 14 of the glycogen synthase gene (GYS1) has been associated with lower glycogen synthase activity, T2D, features of the metabolic syndrome (MetS) and with myocardial infarction in males [4]-[8] but association to T2D has not been consistently replicated in all studies [9], [10]. Interestingly, electrical stimulation of skeletal muscle to mimic physical exercise increased the amount of glycogen synthase in carriers of wild-type C-allele but not in carriers of the T-allele. As a consequence, carriers of the T-allele may benefit less from physical exercise than carriers of the normal allele [11]. GYS1 is located on chromosome 19q13.3, a region that has in several linkage studies been linked to MetS and T2D associated phenotypes [12]-[17]. Further, the GYS1 locus was in the HERITAGE family study linked to glucose effectiveness in response to endurance exercise [18].
###end p 10
###begin p 11
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Mahley1">[19]</xref>
###xml 373 377 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-SingCF1">[20]</xref>
###xml 379 383 373 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Ehnholm1">[21]</xref>
###xml 422 426 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Wilson1">[22]</xref>
###xml 428 432 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Song1">[23]</xref>
###xml 480 484 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 498 506 492 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 558 562 552 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 562 566 556 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Artiga1">[24]</xref>
###xml 643 647 637 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Ye1">[25]</xref>
###xml 693 697 687 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Lambert1">[26]</xref>
GYS1 is separated only by 4.1 million base pairs from the gene coding for apolipoprotein E (APOE), which constitutes three common genetic isoforms in plasma and is known to play an important role in lipid metabolism [19]. The APOE4 isoform encoded by the epsilon4 allele is associated with elevated serum total- and low density lipoprotein (LDL)-cholesterol concentrations [20], [21] and with coronary heart disease (CHD) [22], [23]. In addition, a -219 (G>T) polymorphism in the APOE promoter has in vitro been shown to decrease transcriptional activity of APOE[24] and has been reported to associate with severity of coronary artery disease [25] and increased risk for myocardial infarction [26].
###end p 11
###begin p 12
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 466 470 466 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 660 664 660 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 710 714 710 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Given the considerations above, we set out to test 1) whether the GYS1 polymorphism is associated with CV mortality in individuals from a large T2D family study from Finland, the Botnia Study. In particular we were interested in putative gender differences as the GYS1 polymorphism has earlier been associated with myocardial infarction only in males, 2) whether physical exercise would act as an environmental factor interacting with the effect associated with the GYS1 polymorphism as this has earlier been shown to be associated with defect in stimulation of glycogen synthase protein levels after muscle stimulation, and 3) to test if our results with the GYS1 polymorphism are independent of the adjacent APOE. As the endpoint we used CV mortality after a median follow up period of 8 years.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Study Population
###end title 14
###begin p 15
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Groop2">[27]</xref>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Isomaa1">[28]</xref>
###xml 2247 2251 2241 2245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Alberti1">[29]</xref>
###xml 2333 2335 2327 2329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IR</sub>
The Botnia Study was initiated in 1990 and represents a large population-based family study in Finland and Sweden aiming at identification of genes increasing susceptibility to T2D, MetS and related disorders. Details of the study cohort, sampling strategy as well as anthropometric and metabolic measurements have been described in detail [27], [28]. The study protocol was approved by the local ethics committees and an informed consent was obtained from each subject before participating in the study. The present study was restricted to the original Botnia cohort of 4654 subjects from 965 families (2142 males, 2512 females, age 58.2+/-13.8 years) from Western Finland. At the baseline examination, a structured questionnaire was completed by specially trained nurses, covering information about diseases other than T2D (particularly hypertension, coronary heart disease, myocardial infarction and stroke) and data on smoking habits and physical activity during work and leisure time. Both previous and current smokers were recorded as smokers. Physical activity level during work was defined on a scale from 0 to 6 according to level of physical activity (0 coding for no work and 6 for highest level) while physical activity during leisure time was estimated by a scale from 1 to 3 (1 = almost no activity at all; 2 = sometimes, but not regular; 3 = regular physical activity). Information on work and leisure time physical activity was combined to obtain an estimate of total physical activity level and classified as: 1) no physical activity or low physical activity (work level of 0 to 2 in combination of leisure time level of 1); 2) normal to high physical activity (work activity level 0-2 in combination of leisure time activity of >1; or work activity level >/=3 in combination of any leisure time activity level). When division between high and normal physical activity was needed, normal physical activity was defined as work activity level >/=3 and leisure time of <3 and high physical activity was defined as leisure time activity of 3 in combination with any work activity level. Glucose tolerance, assessed by an oral glucose tolerance test, and MetS were defined according to current World Health Organization (WHO) criteria [29]. Insulin resistance was estimated as the Homeostasis Model Assessment index (HOMAIR = fasting serum insulin*fasting plasma glucose/22.5).
###end p 15
###begin p 16
###xml 200 202 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 311 313 311 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
Total and CV mortality was assessed with median follow up time of 7.9 years and mortality data were obtained from central death-certificate registry in Finland. CV mortality was classified using the 9th revision of the International Classification of Diseases (CV diagnosis codes 390-459) before 1997 and the 10th revision (codes 100-199) thereafter. Causes of death were classified as 1) CV death (CHD, cerebrovascular disease (including both thrombotic stroke and cerebral haemorrhage) or other CV events (including pulmonary embolism, abdominal aortic aneurysm, hypertensive complications, general atherosclerosis and peripheral artery disease with gangrene) or 2) other causes of death (neoplasma, violent or other).
###end p 16
###begin title 17
Genotyping
###end title 17
###begin p 18
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 372 376 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 555 559 555 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 564 568 564 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 595 599 595 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 645 649 621 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 691 695 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 821 825 797 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 831 834 807 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Groop1">[4]</xref>
###xml 836 839 812 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-OrhoMelander1">[7]</xref>
###xml 841 844 817 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Fenger1">[8]</xref>
###xml 860 864 836 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 894 898 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Wilson1">[22]</xref>
###xml 900 904 876 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Ye1">[25]</xref>
###xml 906 910 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Lambert1">[26]</xref>
###xml 994 998 970 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 1118 1122 1094 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-SchalinJantti1">[30]</xref>
A total of 4654 subjects were genotyped for the XbaI polymorphism in intron 14 (rs8103451) of GYS1 and for the APOE isoforms encoded by amino acid substitutions at residues 112 (rs429358) and 158 (rs7412), for the -219G>T promoter polymorphism (rs405509). The XbaI polymorphism in GYS1 was genotyped using single base pair extension on AB3100 (Applied Biosystems) and the APOE polymorphisms were genotyped using allelic discrimination on AB7900 at the SWEGENE DNA genotyping Laboratory. Before any analyses were performed, the expected risk-genotypes for GYS1 and APOE were defined as CT or TT (GYS1 XbaI), epsilon3epsilon4 or epsilon4epsilon4 (APOE codon 112 and 158 polymorphisms) and TT (APOE -219 polymorphism), respectively. Risk-alleles were defined according to previous T2D and MetS association study results for GYS1 XbaI [4], [7], [8] and reports on APOE and risk of coronary disease [22], [25], [26]. To assure high quality of the produced genotypes, a random sample of 17.8% of all GYS1 XbaI genotypes were repeated using PCR and restriction fragment length polymorphism and the concordance rate was 99.9% [30].
###end p 18
###begin title 19
Statistical Analysis
###end title 19
###begin p 20
###xml 72 73 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Allele- and genotype frequencies between groups were compared by the chi2 test or by Fisher's exact test whereas multiple regression was used to compare clinical variables between groups, adjusting for age, sex and BMI. Hardy-Weinberg equilibrium (HWE) was tested using exact test () with alpha level of <0.05 for rejection. For the survival analyses the data were treated as left truncated and right censored, meaning that age was the basic time variable. Survival curves were obtained with the Kaplan-Meier estimator, and nonparametric two-sample tests for genetic effects were performed with the log-rank test. Covariates from the baseline visit were used. Effects of genetic and clinical variables on survival time were analysed with uni- and multivariate Cox regression analyses, stratified for sex and using a robust variance estimate to adjust for within family dependence by treating each pedigree as an independent entity when calculating the variance. The univariate analyses were performed to obtain relevant set of variables for multivariate analyses, therefore these p-values were not corrected for multiple testing. The multivariate Cox models were obtained by stepwise forward inclusion of the covariates and statistical significance of the model was analysed using the Wald test. Individuals with missing data for any of the covariates were excluded from the analyses. Due to missing data on microalbuminuria (data missing for 35%) this variable was not included in the multivariate analysis.
###end p 20
###begin p 21
###xml 401 405 401 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 473 477 473 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 559 563 559 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 721 722 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
Multiple tests were performed within the study (2 genes with 3 polymorphic sites and subanalyses in males and females). Concerning the XbaI polymorphism in males subanalyses were also performed according to physical activity level (low or normal to high). We did not correct for the number of analysed genes and polymorphisms as this study was designed to test the hypothesis that the T-allele of the GYS1 XbaI polymorphism could be associated with CV mortality and as the APOE markers were studied to test if the GYS1 results are independent of the adjacent APOE. For the gender-specific analyses and for the analyses in individuals with different physical activity levels we report both non-adjusted (p) and adjusted (pc) p-values. The gender-specific analyses were multiplied with a factor of 3 (3 groups; all, males, females) and the physical activity analyses with a factor of 6 (3 groups with either low or normal to high physical activity).
###end p 21
###begin p 22
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Barrett1">[31]</xref>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Casella1">[32]</xref>
All statistical analyses were performed using Number Crunching Statistical Systems version 2004 (NCSS; Kaysville, Utah, USA) or R (). Two sided p-values of less than 0.05 were considered statistically significant. Estimates of linkage disequilibrium were calculated using the Haploview program [31]. Power calculations were performed using the normal distributions for the coefficient estimates in the Cox regression model [32].
###end p 22
###begin title 23
Results
###end title 23
###begin title 24
Clinical and metabolic risk factors for CV mortality
###end title 24
###begin p 25
###xml 132 139 132 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t001">Table 1</xref>
###xml 988 995 988 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t001">Table 1</xref>
During a median follow-up time of 7.9 years, 749 of the 4654 individuals (16.1%) had died and of them 409 (54.6%) due to CV causes (Table 1). Total mortality was slightly higher among males than among females (17.4 vs. 15.0%, p = 0.029), while frequency of CV mortality did not significantly differ between males and females (9.2 vs. 8.4%, p = 0.32). Subjects who died of CV causes had lower high density lipoprotein (HDL) cholesterol levels compared to both living subjects (p<0.0001) and individuals who died of other than CV causes (p = 0.0009). They also had higher triglyceride levels (p<0.0001) and higher frequency of T2D (p<0.0001), MetS (p = 0.0002), hypertension (p = 0.015), microalbuminuria (p<0.0001), earlier CV events (<0.0001) and lower physical activity level than subjects who were alive. CV death was associated with higher BMI (p = 0.046), total cholesterol levels (p = 0.0037), frequency of T2D (p<0.0001) and earlier CV events (p<0.0001) than death of other causes (Table 1).
###end p 25
###begin p 26
###xml 248 255 248 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t002">Table 2</xref>
###xml 627 634 627 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t002">Table 2</xref>
Male gender, abdominal obesity, dyslipidaemia, T2D, hypertension, microalbuminuria, earlier CV events, smoking and low physical activity level were significant predictors of CV mortality among all individuals in univariate Cox regression analyses (Table 2). Gender specific univariate analyses identified low HDL cholesterol, T2D, hypertension, microalbuminuria, earlier CV events and physical inactivity as significant risk factors in both genders. Smoking was a significant risk factor only among male subjects while abdominal obesity and elevated triglyceride levels were significant predictors of CV death only in females (Table 2).
###end p 26
###begin p 27
###xml 191 198 191 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t003">Table 3</xref>
###xml 369 376 369 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t004">Table 4</xref>
In multivariate analyses T2D, elevated fasting insulin concentration, earlier CV events, low physical activity and smoking were significant risk factors for CV mortality in males (model 1 in Table 3). In females T2D, high fasting glucose concentration, hypertension, earlier CV events, and physical inactivity were significant risk factors for CV mortality (model 1 in Table 4). Due to lack of data for a large part (35%) of the study subjects, microalbuminuria was not included in the multivariate model.
###end p 27
###begin title 28
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Allelic association between the GYS1 and APOE polymorphisms
###end title 28
###begin p 29
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 420 424 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 459 463 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 681 685 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 817 821 721 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 896 900 800 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 908 909 812 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 959 963 863 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Genotype frequencies of the GYS1 XbaI polymorphisms and APOE in the study population were: GYS1 XbaI C/T (CC 88.0%, CT 11.5%, TT 0.6%), APOE -219G>T (GG 29.5%, GT 50.2%, TT 20.3%), and APOE epsilon2/epsilon3/epsilon4 (epsilon2epsilon2 0.4%, epsilon2epsilon3 9.4%, epsilon2epsilon4 2.3%, epsilon3epsilon3 59.4%, epsilon3epsilon4 25.2%, epsilon4epsilon4 3.2%). The genotypes of all single nucleotide polymorphisms (SNPs) (APOE Cys112Arg, Arg158Cys, -219G>T and GYS1 XbaI) and the relative frequencies of epsilon-alleles, were in Hardy Weinberg equilibrium in the whole study population. Neither the genotype frequencies nor their combinations differed between males and females. The APOE -219G>T and Arg158Cys as well as the Arg158Cys and Cys112Arg polymorphisms were in complete linkage disequilibrium (D' = 1.0). The GYS1 XbaI polymorphism was not in linkage disequilibrium with any of the three APOE SNPs (r2 = 0.0, for all and D' = 0.12, 0.07 and 0.16, for APOE-219G>T, Cys112Arg and Arg158Cys, respectively).
###end p 29
###begin title 30
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
GYS1 XbaI as a genetic predictor for CV mortality
###end title 30
###begin p 31
###xml 222 229 222 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t005">Table 5</xref>
###xml 383 384 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 525 532 525 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t002">Table 2</xref>
###xml 537 546 537 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000285-g001">Figure 1A</xref>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
The frequency of the XbaI risk genotypes (CT or TT) did not significantly differ between patients who died of CV causes, other causes or survivors when all subjects were included in the analyses (13.3%, 10.5%, and 12.0%) (Table 5). However, in gender-specific analyses, males with CV death had more often the CT/TT genotypes compared to surviving males (19.2 vs. 11.8%, p = 0.0038, pc = 0.011). Consequently, in the Cox regression analysis, the GYS1 XbaI CT/TT genotypes were significant predictors of CV mortality in males (Table 2 and Figure 1A). The CT/TT genotypes did not predict mortality due to other than CV causes.
###end p 31
###begin p 32
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 190 197 190 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t003">table 3</xref>
Furthermore, when analysed together the GYS1 XbaI polymorphism, T2D, earlier CV events, low physical activity and smoking were significant risk factors for CV mortality in males (model 2 in table 3).
###end p 32
###begin title 33
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
Does physical activity influence the effect associated with the genetic variation in GYS1 on CV mortality risk?
###end title 33
###begin p 34
###xml 578 579 578 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 644 645 644 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 1039 1040 1039 1040 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 1050 1058 1050 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000285-g002">Figure 2</xref>
CV mortality was significantly higher among individuals with low physical activity level compared to individuals with normal (29.9 vs. 7.1%, p<0.0001, corrected for sex and age) or high (29.9 vs. 5.7%, p<0.0001) physical activity level. The difference was not significant between groups reporting normal or high physical activity level (7.1 vs. 5.4%, p = 0.35) suggesting minimal or no protective effect above a normal level of physical activity on CV mortality risk. In a multivariate Cox regression analysis both physical activity (hazard ratio (HR) 3.2 [2.2-4.6], p<0.0001, pc<0.0001) and the XbaI polymorphism (HR 2.6 [1.7-3.8], p<0.0001, pc<0.0001) were strongly associated with CV mortality. While physical activity itself (normal or high) had a strong protective effect on CV mortality, this effect was attenuated in carriers of the CT/TT-genotypes of the XbaI polymorphism; physically active males with the CT/TT genotypes had a 2.7-times higher risk for CV mortality compared to CC-genotype carriers (HR 2.7 [1.8-4.1], p<0.0001, pc<0.0001) (Figure 2).
###end p 34
###begin title 35
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
APOE polymorphisms as genetic predictors for CV mortality
###end title 35
###begin p 36
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 112 116 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 177 181 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 193 197 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 312 319 258 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t005">Table 5</xref>
###xml 384 388 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 496 497 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 539 540 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 569 573 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 663 667 603 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 773 780 707 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t002">Table 2</xref>
###xml 785 794 719 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000285-g001">Figure 1B</xref>
###xml 918 922 852 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 1116 1123 1050 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000285-t004">table 4</xref>
The frequency of the APOE epsilon2/epsilon3/epsilon4 risk genotypes (epsilon3epsilon4 or epsilon4epsilon4), the APOE -219 risk genotype (TT) or the risk genotype combination of APOEepsilon and APOE -219 (-219TT/epsilon4) did not significantly differ between individuals who died of CV causes and other subjects (Table 5). However, females in the CV mortality group had more often the APOE -219 TT-genotype, in particular -219TT/epsilon4 compared to surviving females (26.9 vs. 19.8%, p = 0.019, pc = 0.057 and 17.5 vs. 9.4%, p = 0.00048, pc = 0.0014). No effect of the APOE variants was observed in males, this effect being restricted to females in whom both the APOE epsilon4-allele, the -219 TT-genotype and their combination were significant predictors of CV mortality (Table 2 and Figure 1B), but not of non-CV mortality. When genetic and non-genetic factors were included in the analysis of risk of CV death, the APOE risk genotype combination, high fasting glucose level, high BMI, hypertension, earlier CV events and low physical activity were significant risk factors for CV mortality in females (model 2 in table 4).
###end p 36
###begin title 37
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Cholesterol levels and CV mortality according to APOE epsilon3epsilon4/epsilon4epsilon4 and -219 TT genotypes
###end title 37
###begin p 38
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 248 252 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 415 416 363 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 567 568 487 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 582 586 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 644 648 564 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 690 691 610 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 811 815 731 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 902 906 798 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 984 985 856 857 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
The APOE epsilon3epsilon4/epsilon4epsilon4 and -219 TT genotypes (and their combination) were associated with increased total and LDL cholesterol levels in both males and females (after adjustment for age, T2D and BMI). Interestingly, although the APOE epsilon3epsilon4/epsilon4epsilon4 variants had a statistically weaker effect on total cholesterol in female carriers (6.1+/-1.2 vs. 5.8+/-1.2 mmol/l, p = 0.014, pc = 0.084 for the epsilon3epsilon4/epsilon4epsilon4 genotype vs. other genotypes) compared to non-carriers (6.1+/-1.2 vs. 5.8+/-1.1 mmol/l, p = 0.0001 pc = 0.0006) of APOE -219 TT, they only predicted CV mortality in carriers of APOE -219 TT (HR 2.3, [1.3-4.2], p = 0.0059, pc = 0.035). The -219 polymorphism had no effect on cholesterol levels neither in female carriers nor non-carriers of the APOE epsilon3epsilon4/epsilon4epsilon4, and predicted CV mortality only in carriers of the APOE epsilon3epsilon4/epsilon4epsilon4 genotypes (HR 2.3 [1.5-3.6], p = 0.00038, pc = 0.0023).
###end p 38
###begin p 39
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 280 281 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 364 368 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 406 410 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 523 527 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 605 609 525 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 648 652 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
In males, the APOE epsilon3epsilon4/epsilon4epsilon4 genotypes affected total cholesterol in carriers (5.9+/-1.0 vs. 5.6+/-1.2 mmol/l, p = 0.031, for the epsilon3epsilon4/epsilon4epsilon4 genotype vs. other genotypes, respectively) but not after correcting for multiple testing (pc = 0.19) and not in non-carriers (5.7+/-1.0 vs. 5.6+/-1.1 mmol/l, p = 0.31) of the APOE -219 TT genotype. As in females, the APOE -219 TT genotype had no significant effect on cholesterol values neither in carriers nor in non-carriers of the APOE epsilon3epsilon4/epsilon4epsilon4 genotypes. In contrast to females, neither APOE epsilon3epsilon4/epsilon4epsilon4 nor APOE -219 TT predicted CV mortality in males.
###end p 39
###begin title 40
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Independency between GYS1 and APOE as risk factors for CV mortality
###end title 40
###begin p 41
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 247 251 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 303 307 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 367 371 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 405 409 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 443 447 431 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 640 644 628 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 649 653 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 737 741 725 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 795 799 783 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
To investigate whether the 'at-risk' genotypes of GYS1 and APOE contributed independently to the CV mortality risk, we performed Cox regression analyses by entering both genes into the equation. These analyses clearly indicated that the effect of GYS1 XbaI CT/TT in males (XbaI CT/TT: HR 1.9 [1.3-2.7], APOE -219/epsilon4: HR 1.5 [0.9-2.5]), as well as the effect of APOE genotype combination in females (APOE -219/epsilon4: HR 2.4 [1.7-3.6], GYS1 XbaI CT/TT: HR 1.3 [0.8-2.3]), were independent of each other. To further assess the independence of the effects of the polymorphisms on CV mortality, the samples were stratified according to GYS1 and APOE genotypes: The XbaI T-allele was associated with CV mortality in males without the APOE risk genotype combination (HR 1.9 [1.3-2.8]) and the APOE risk-genotype combination was associated with cardiovascular mortality among female XbaI CC-carriers (HR 2.3 [1.6-3.5]).
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 319 323 319 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 429 433 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 607 611 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
The key findings of the present study were that 1) the XbaI polymorphism in GYS1 was associated with CV mortality in males; 2) although physical activity markedly reduces risk of CV death, this protective effect was attenuated in male carriers of the XbaI polymorphism; and 3) despite the fact that GYS1 is adjacent to APOE on chromosome 19q13, the effect of the GYS1 polymorphism on CV mortality is independent of the effect of APOE, which exerts a strong effect on CV mortality risk by its own. Interestingly, this risk seems to be restricted to females and cannot fully be explained by the effect of the APOE alleles on cholesterol levels.
###end p 43
###begin p 44
###xml 121 125 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Ober1">[33]</xref>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Heijmans1">[37]</xref>
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Pollin1">[38]</xref>
###xml 168 172 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Bell1">[39]</xref>
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Feitosa1">[40]</xref>
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Pratley1">[12]</xref>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-An1">[17]</xref>
###xml 529 533 529 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-An2">[18]</xref>
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Weiss1">[41]</xref>
###xml 627 631 627 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 636 640 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 729 733 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
Several studies performed in different ethnic populations have reported linkage to chromosome 19q13 for LDL-cholesterol- [33]-[37] or triglyceride levels [38], obesity [39], [40], as well as for insulin resistance and T2D related phenotypes [12]-[17] but the underlying genetic variants have not been identified. In addition, glucose effectiveness in response to exercise training as well as significant sex specific differences in heritability models and sex interaction for HDL cholesterol have been mapped to the 19q13 region [18], [41]. We therefore set out to study the contribution of two candidate genes in this region, GYS1 and APOE to CV mortality risk, focusing particularly on the role of putative interaction between GYS1 polymorphism and gender and/or physical activity level to affect the CV mortality rate.
###end p 44
###begin p 45
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 281 284 281 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-OrhoMelander1">[7]</xref>
The GYS1 XbaI polymorphism was significantly associated with increased risk for CV mortality in males, a result supported by our previous independent finding of an association between myocardial infarction and this particular polymorphism only in males in another study population [7].
###end p 45
###begin p 46
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-StOnge1">[11]</xref>
###xml 490 494 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-StOnge1">[11]</xref>
As anticipated, a low physical activity level was a severe risk factor for CV mortality. The novel finding of our study was that the protective effect of physical exercise was attenuated in carriers of the XbaI polymorphism. This goes along with the hypothesis advanced by a Canadian study [11] that carriers of the risk T-allele have a defect in their ability to increase the glycogen synthase protein in response to neuromuscular electrical stimulation (as a proxy for physical exercise) [11]. An increase in glycogen synthase protein would promote glycogen formation which, in turn, could have a beneficial effect on exercise capacity. The downside of this message is that all individuals would not respond to physical exercise in the same way. The positive message is that the "non-responder" group is relatively small (frequency of CT/TT genotypes in the population is only 12%) and in 88% of the population exercise exerts a highly beneficial and protective effect on risk of CVD.
###end p 46
###begin p 47
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Shephard1">[42]</xref>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Shephard1">[42]</xref>
###xml 718 722 718 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-CamperKirby1">[43]</xref>
###xml 141 146 <span type="species:ncbi:9606">women</span>
###xml 196 199 <span type="species:ncbi:9606">men</span>
###xml 296 301 <span type="species:ncbi:9606">women</span>
###xml 712 717 <span type="species:ncbi:9606">woman</span>
We have no apparent explanation for why the effect of the XbaI polymorphism was restricted to males. One potential explanation could be that women have less muscle mass and muscular strength than men, but also a tendency to metabolise fat rather than carbohydrate during exercise [42]. Moreover, women seem less vulnerable to exercise-induced sudden death [42]. A potential explanation could be that both exercise training and oestrogen increase Akt phosphorylation and glycogen synthase kinase-3 inactivation leading to increased glycogen synthase activity. Interestingly, markedly higher myocardial Akt nuclear activity has been reported in females than in males as well as in pre- compared to post-menopausal woman [43]. If this also applies to skeletal muscle it could provide a potential explanation for the observed gender-specific effect.
###end p 47
###begin p 48
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 103 107 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 166 170 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Wilson1">[22]</xref>
###xml 172 176 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Song1">[23]</xref>
###xml 178 182 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Ye1">[25]</xref>
###xml 184 188 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Lambert1">[26]</xref>
###xml 342 346 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 616 620 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 1041 1045 1035 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Dupont1">[44]</xref>
###xml 1138 1142 1132 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000285-Casella1">[32]</xref>
###xml 387 395 <span type="species:ncbi:9606">patients</span>
###xml 424 427 <span type="species:ncbi:9606">men</span>
###xml 476 481 <span type="species:ncbi:9606">women</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 709 712 <span type="species:ncbi:9606">men</span>
###xml 717 722 <span type="species:ncbi:9606">women</span>
###xml 964 972 <span type="species:ncbi:9606">patients</span>
Our results are in agreement with the earlier results reporting either the APOE epsilon4-allele or the APOE -219 TT-genotype as risk factors for CVD and/or mortality [22], [23], [25], [26] but, interestingly, we could observe this effect only in females. Caution is, however, warranted in the interpretation of the gender-specific effects of APOE as the study included a large number of patients with T2D. It is known, that men with T2D have an excess mortality compared with women with T2D resulting in a relative increase in the frequency of female T2D patients with aging. It is therefore still possible that the APOE polymorphisms had an effect in male T2D resulting in premature death. A sub-analysis of men and women divided by the median of age did, however, not support such an explanation. Also, power is reduced when the analysis is restricted to gender. The power in a Cox regression analysis depends among other things on the accrual time during which patients are recruited, mean time to failure and the expected effect sizes ()[44]. We used the standard Normal theory to calculate the power to detect a HR of a certain size [32]. Our study had a 73-96% power to detect hazard ratios of 1.5 for the analysed polymorphisms.
###end p 48
###begin p 49
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
In conclusion, we demonstrate a protective effect of physical activity on CV mortality. However, in male subjects this effect was attenuated in carriers of the rare allele of the XbaI polymorphism in GYS1. This finding could be compatible with a previous demonstration of defective increase in the glycogen synthase protein in carriers of this polymorphism. We could exclude that the association between the GYS1 polymorphism and CV mortality was due to the adjacent APOE gene. Instead, we demonstrated that this gene exerted an increased risk of CV mortality in females. These findings re-emphasize the need to consider the effect of genetic variants in complex diseases in concert with their environmental triggers but also to evaluate whether females and males respond differently to genes and the environment.
###end p 49
###begin title 50
References
###end title 50
###begin article-title 51
National Heart, Lung and Blood Institute. NHLBI morbidity and mortality chartbook.
###end article-title 51
###begin article-title 52
Summary of the second report of the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel II).
###end article-title 52
###begin article-title 53
Sexual dimorphism in mammalian gene expression.
###end article-title 53
###begin article-title 54
Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus.
###end article-title 54
###begin article-title 55
Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus.
###end article-title 55
###begin article-title 56
###xml 44 50 <span type="species:ncbi:9606">people</span>
Impaired activation of glycogen synthase in people at increased risk for developing NIDDM.
###end article-title 56
###begin article-title 57
A paired-sibling analysis of the XbaI polymorphism in the muscle glycogen synthase gene.
###end article-title 57
###begin article-title 58
###xml 39 44 <span type="species:ncbi:9606">human</span>
Impact of the Xba1-polymorphism of the human muscle glycogen synthase gene on parameters of the insulin resistance syndrome in a Danish twin population.
###end article-title 58
###begin article-title 59
Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus.
###end article-title 59
###begin article-title 60
###xml 68 76 <span type="species:ncbi:9606">patients</span>
New variants in the glycogen synthase gene (Gln71His, Met416Val) in patients with NIDDM from eastern Finland.
###end article-title 60
###begin article-title 61
The stimulation-induced increase in skeletal muscle glycogen synthase content is impaired in carriers of the glycogen synthase XbaI gene polymorphism.
###end article-title 61
###begin article-title 62
An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians.
###end article-title 62
###begin article-title 63
The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. II. An autosomal genome scan for diabetes-related quantitative-trait loci.
###end article-title 63
###begin article-title 64
Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p.
###end article-title 64
###begin article-title 65
###xml 64 71 <span type="species:ncbi:9606">persons</span>
A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study.
###end article-title 65
###begin article-title 66
A genome-wide scan in type 2 diabetes mellitus provides independent replication of a susceptibility locus on 18p11 and suggests the existence of novel Loci on 2q12 and 19q13.
###end article-title 66
###begin article-title 67
Genome-wide linkage scans for fasting glucose, insulin, and insulin resistance in the National Heart, Lung, and Blood Institute Family Blood Pressure Program: evidence of linkages to chromosome 7q36 and 19q13 from meta-analysis.
###end article-title 67
###begin article-title 68
Genome-wide linkage scans for prediabetes phenotypes in response to 20 weeks of endurance exercise training in non-diabetic whites and blacks: the HERITAGE Family Study.
###end article-title 68
###begin article-title 69
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.
###end article-title 69
###begin article-title 70
Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation.
###end article-title 70
###begin article-title 71
Apolipoprotein E polymorphisms in the Finnish population: gene frequencies and relation to lipoprotein concentrations.
###end article-title 71
###begin article-title 72
Apolipoprotein E alleles and risk of coronary disease. A meta-analysis.
###end article-title 72
###begin article-title 73
Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease.
###end article-title 73
###begin article-title 74
Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene.
###end article-title 74
###begin article-title 75
Independent effects of the -219 G>T and epsilon 2/ epsilon 3/ epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study.
###end article-title 75
###begin article-title 76
Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study.
###end article-title 76
###begin article-title 77
Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects.
###end article-title 77
###begin article-title 78
Cardiovascular morbidity and mortality associated with the metabolic syndrome.
###end article-title 78
###begin article-title 79
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [see comments].
###end article-title 79
###begin article-title 80
Polymorphism of the glycogen synthase gene in hypertensive and normotensive subjects.
###end article-title 80
###begin article-title 81
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 81
###begin article-title 82
The genetic dissection of complex traits in a founder population.
###end article-title 82
###begin article-title 83
Evidence for a QTL on chromosome 19 influencing LDL cholesterol levels in the general population.
###end article-title 83
###begin article-title 84
Genome-wide linkage scan reveals multiple susceptibility loci influencing lipid and lipoprotein levels in the Quebec Family Study.
###end article-title 84
###begin article-title 85
A genome wide quantitative trait linkage analysis for serum lipids in type 2 diabetes in an African population.
###end article-title 85
###begin article-title 86
Meta-analysis of four new genome scans for lipid parameters and analysis of positional candidates in positive linkage regions.
###end article-title 86
###begin article-title 87
A genome-wide scan of serum lipid levels in the Old Order Amish.
###end article-title 87
###begin article-title 88
Genome-wide linkage analysis for severe obesity in french caucasians finds significant susceptibility locus on chromosome 19q.
###end article-title 88
###begin article-title 89
Pleiotropic QTL on chromosome 19q13 for triglycerides and adiposity: The HERITAGE family study.
###end article-title 89
###begin article-title 90
###xml 64 70 <span type="species:ncbi:9606">humans</span>
The sex-specific genetic architecture of quantitative traits in humans.
###end article-title 90
###begin article-title 91
###xml 25 30 <span type="species:ncbi:9606">women</span>
Exercise and training in women, Part I: Influence of gender on exercise and training responses.
###end article-title 91
###begin article-title 92
Myocardial Akt activation and gender: increased nuclear activity in females versus males.
###end article-title 92
###begin article-title 93
PS: Power and Sample Size Calculation
###end article-title 93
###begin title 94
Figures and Tables
###end title 94
###begin title 95
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
CV mortality in males and females according to the GYS1 XbaI (A) and APOE -219/epsilon2/epsilon3/epsilon4 (B) genotypes.
###end title 95
###begin p 96
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 269 270 263 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
Kaplan Meier survival curves illustrating a higher risk for CV mortality (HR 1.8 [1.2-2.6], p = 0.0016, pc = 0.0096) in male carriers of the GYS1 XbaI CT/TT-genotypes and in female carriers of the APOE -219TT/epsilon4 genotype combination (HR 2.3 [1.6-3.2], p<0.0001, pc<0.0001).
###end p 96
###begin title 97
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
Interaction between the GYS1 XbaI polymorphism and physical activity (PA) in males.
###end title 97
###begin p 98
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
Kaplan Meier survival curves for males reporting normal to high physical activity (PA) level according to GYS1 XbaI genotype compared to males with low PA level.
###end p 98
###begin title 99
CHARACTERISTICS OF THE STUDY SUBJECTS
###end title 99
###begin p 100
BMI; body mass index, WH; waist to hip ratio
###end p 100
###begin title 101
CLINICAL AND GENETIC RISK FACTORS FOR CV MORTALITY
###end title 101
###begin p 102
Univariate Cox proportional-hazards analysis, performed with robust variance estimate to adjust for within family dependence. BMI; body mass index, WH; waist to hip ratio
###end p 102
###begin title 103
MULTIVARIATE MODEL OF RISK FACTORS FOR CV MORTALITY IN MALES
###end title 103
###begin p 104
###xml 152 153 152 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
Multivariate Cox regression analysis using stepwise forward inclusion with robust variance estimates. Adjusted for age, sex and family correlations. * Pc = 0.018
###end p 104
###begin title 105
MULTIVARIATE MODEL OF RISK FACTORS FOR CV MORTALITY IN FEMALES
###end title 105
###begin p 106
###xml 152 153 152 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 160 162 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
Multivariate Cox regression analysis using stepwise forward inclusion with robust variance estimates. Adjusted for age, sex and family correlations. * Pc = 7.8e-6
###end p 106
###begin title 107
GENOTYPE DISTRIBUTION IN SUBJECTS WHO DIED FROM CV CAUSES AND IN SUBJECTS WHO ARE ALIVE OR DIED DUE TO OTHER CAUSES
###end title 107
###begin p 108
###xml 35 36 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 66 67 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 105 106 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
Fischer's exact test, *p = 0.019 (pc = 0.057), daggerp = 0.0038 (pc = 0.011), double daggerp = 0.00048 (pc = 0.0014)
###end p 108
###begin p 109
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 109
###begin p 110
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the Diabetes Program at Lund University (DPLU), the Foundation for Strategic Research through the National Network for Cardiovascular Research, the Swedish Medical Research Council, the Swedish Foundation for the Study of Diabetes, the Albert Pahlssons Foundation, Malmo University Hospital Foundation, Crafoord Foundation, the Lundberg Foundation, the Novo Nordisk Foundation, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University and EXGENESIS CT-2004-005272. The Botnia Study is principally supported by the Sigrid Juselius Foundation, the Academy of Finland, the Finnish Diabetes Research Foundation, the Folkhalsan Research Foundation, and the Viktor Ollqvist Foundation.
###end p 110

